Vitalik Buterin supports AI company Anthropic in resisting the White House's demand for military technology use

Arcadia Healthcare recently disclosed that policy changes in New York State’s Medicaid program regarding out-of-state facility care services are expected to have a negative impact of $25 million to $30 million on its adjusted EBITDA for 2026.

Ironwood Pharmaceuticals officially released its financial report for the fourth quarter and full year of 2025 today.

Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria.

According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), the Audit Committee of Driven Brands Holdings Inc. discovered significant errors in the company’s fiscal year 2024 financial statements during its review.